TY - JOUR T1 - Iodine-125 seed brachytherapy combined with pembrolizumab for advanced non-small-cell lung cancer after failure of first-line chemotherapy JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA2182 VL - 58 IS - suppl 65 SP - PA2182 AU - Mingli Yuan AU - Yi Hu AU - Liangchao Wang AU - Yang Xiao AU - Xiaoqun Guo Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA2182.abstract N2 - In our report, two patients with advanced NSCLC with negative targetable mutations, who had failed in the first-line chemotherapy, were treated with combined therapy of computed tomography (CT)-guided percutaneous iodine-125 seed implantation (ISI) and pembrolizumab and both patients acheived partial response. Table summarizes the clinical data. ParametersCase 1Case 2Age, y5772SexMaleMalePathologyLung adenocarcinomaLung squamous carcinomaStageT4N3M1c, ⅣBT4N3M0, ⅢCTPS70%1%Region of radiotherapyRight upper lobeAnterior mediastinumParticle activity, mCi0.80.8Number of particles2674Prescribed dose, Gy140140Fig. 1 (A)CT upon admission.(B) CT after 4 cycles of chemotherapy. (C) CT following 20 cycles of chemotherapy. (D) CT after discontinued treatment for 3 months. (E) CT following ISI combined with pembrolizumab treatment for 8 cycles and that was 26 months after initial diagnosis.Fig. 2 (A) CT upon admission. (B) CT after 3 cycles of chemotherapy. (C) CT following ISI combined with pembrolizumab treatment for 8 cycles and that was 16 months after initial diagnosis.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2182.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -